Literature DB >> 24054440

Dietary management of idiopathic hyperoxaluria and the influence of patient characteristics and compliance.

Zeyad R Schwen1, Julie M Riley, Yaniv Shilo, Timothy D Averch.   

Abstract

OBJECTIVE: To assess the efficacy of dietary management for the treatment of idiopathic hyperoxaluria in a large tertiary care center and examine the influence of patient factors, compliance, and follow-up on oxalate reduction, which has not been previously investigated.
METHODS: Retrospectively, 149 patients with kidney stones with idiopathic hyperoxaluria who received dietary management at our stone clinic were evaluated. Changes in urinary parameters on 24-hour urine collections were calculated for all patients and those with abnormal values in the overall short-term (30-240 days) and long-term (>240 days) time periods. Changes in urinary oxalate were evaluated with respect to patient characteristics and compliance measures.
RESULTS: Urine oxalate and supersaturation of calcium oxalate were significantly (P < .001) reduced by 8.9 ± 19.2 mg/d and 1.7 ± 4.3, respectively. A total of 48.3% of the patients reduced their urinary oxalate to normal. Urine oxalate reductions were similar in the short-term and long-term periods. Women lowered urine oxalate nearly twice as much as men (12.7 ± 2.0 mg/d vs 6.7 ± 2.2 mg/d, P = .022) and body mass index (BMI) negatively correlated with oxalate reduction (Pearson's r = -0.213). Reported noncompliance and keeping follow-up appointments did not affect oxalate, however, there was a significant correlation between increasing urine volume and reducing oxalate (Pearson's r = -0.21).
CONCLUSION: This study confirms that meaningful reductions of urine oxalate and supersaturation of calcium oxalate can be achieved with dietary management of hyperoxaluria on a larger clinical scale. Furthermore, we identified that women and patients with low BMIs had greater urine oxalate reductions and urine volume may also be used by clinicians as a measure of dietary compliance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24054440      PMCID: PMC3864764          DOI: 10.1016/j.urology.2013.08.002

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  29 in total

1.  Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.

Authors:  John C Lieske; William J Tremaine; Claudio De Simone; Helen M O'Connor; Xujian Li; Eric J Bergstralh; David S Goldfarb
Journal:  Kidney Int       Date:  2010-08-25       Impact factor: 10.612

2.  Urologic diseases in America project: urolithiasis.

Authors:  Margaret S Pearle; Elizabeth A Calhoun; Gary C Curhan
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

3.  Diet to reduce mild hyperoxaluria in patients with idiopathic calcium oxalate stone formation: a pilot study.

Authors:  Antonio Nouvenne; Tiziana Meschi; Angela Guerra; Franca Allegri; Beatrice Prati; Enrico Fiaccadori; Umberto Maggiore; Loris Borghi
Journal:  Urology       Date:  2009-02-04       Impact factor: 2.649

4.  Hyperoxaluria in patients with idiopathic calcium nephrolithiasis.

Authors:  A Trinchieri; F Ostini; R Nespoli; F Rovera; G Zanetti; E Pisani
Journal:  J Nephrol       Date:  1998 Mar-Apr       Impact factor: 3.902

5.  Pyridoxine and dietary counseling for the management of idiopathic hyperoxaluria in stone-forming patients.

Authors:  Omar Ortiz-Alvarado; Ricardo Miyaoka; Carly Kriedberg; Angela Moeding; Michelle Stessman; Manoj Monga
Journal:  Urology       Date:  2011-02-19       Impact factor: 2.649

6.  Prevalence of kidney stones in the United States.

Authors:  Charles D Scales; Alexandria C Smith; Janet M Hanley; Christopher S Saigal
Journal:  Eur Urol       Date:  2012-03-31       Impact factor: 20.096

7.  Body size and 24-hour urine composition.

Authors:  Eric N Taylor; Gary C Curhan
Journal:  Am J Kidney Dis       Date:  2006-12       Impact factor: 8.860

8.  Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients.

Authors:  Wesley O Ekeruo; Yeh Hong Tan; Matthew D Young; Philipp Dahm; Michaella E Maloney; Barbara J Mathias; David M Albala; Glenn M Preminger
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

9.  Dietary risk factors for hyperoxaluria in calcium oxalate stone formers.

Authors:  Roswitha Siener; Dagmar Ebert; Claudia Nicolay; Albrecht Hesse
Journal:  Kidney Int       Date:  2003-03       Impact factor: 10.612

10.  Hyperoxaluria in patients with recurrent calcium oxalate calculi: dietary and other risk factors.

Authors:  N A Laminski; A M Meyers; M Kruger; M I Sonnekus; L P Margolius
Journal:  Br J Urol       Date:  1991-11
View more
  5 in total

Review 1.  Environmental and stressful factors affecting the occurrence of kidney stones and the kidney colic.

Authors:  Rigas G Kalaitzidis; Dimitrios Damigos; Kostas C Siamopoulos
Journal:  Int Urol Nephrol       Date:  2014-06-14       Impact factor: 2.370

2.  Analysis and Characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei: Two Probiotic Bacteria that Can Degrade Intestinal Oxalate in Hyperoxaluric Rats.

Authors:  Yogita Mehra; Nachiappa Ganesh Rajesh; Pragasam Viswanathan
Journal:  Probiotics Antimicrob Proteins       Date:  2022-06-14       Impact factor: 5.265

3.  Temporal Trends of Dietary Risk Factors after a Diagnosis of Kidney Stones.

Authors:  Pietro Manuel Ferraro; Tamara Da Silva Cunha; Eric N Taylor; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-19       Impact factor: 10.614

4.  Compliance in patients with dietary hyperoxaluria: A cohort study and systematic review.

Authors:  Derek B Hennessey; Ned Kinnear; Gilbert Rice; David Curry; Siobhan Woolsey; Brian Duggan
Journal:  Asian J Urol       Date:  2018-03-29

5.  An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria.

Authors:  David Lubkowicz; Nicholas G Horvath; Michael J James; Pasquale Cantarella; Lauren Renaud; Christopher G Bergeron; Ron B Shmueli; Cami Anderson; Jian-Rong Gao; Caroline B Kurtz; Mylene Perreault; Mark R Charbonneau; Vincent M Isabella; David L Hava
Journal:  Mol Syst Biol       Date:  2022-03       Impact factor: 11.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.